Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 5/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13709311 | 0.99 | VDR (0.39) | VDRS1PR1CCR2CA1CA12 | |
| SCHEMBL13709275 | 0.86 | CCR2 (0.40) | VDRCCR2HDAC6EPHX2SLC6A9 | |
| SCHEMBL13709314 | 0.86 | CCR2 (0.39) | VDRCCR2HDAC6EPHX2SLC6A9 | |
| SCHEMBL13709273 | 0.86 | CXCR2 (0.33) | VDRCCR2HDAC6EPHX2SLC6A9 | |
| SCHEMBL13709309 | 0.85 | CXCR2 (0.34) | VDRCCR2HDAC6EPHX2SLC6A9 | |
| SCHEMBL13709269 | 0.85 | VDR (0.37) | VDRS1PR1CCR2CA1CA12 | |
| SCHEMBL13709307 | 0.84 | VDR (0.37) | VDRS1PR1CCR2CA1CA12 | |
| SCHEMBL13709292 | 0.82 | VDR (0.30) | VDRCCR2 | |
| SCHEMBL13709322 | 0.81 | — | — | |
| SCHEMBL13709354 | 0.81 | VDR (0.41) | VDRS1PR1CCR2CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595345-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200552-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | VDR 1/4885S1PR1 174/4885CCR2 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.